Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
CA 2514058 C · Owner: Jakobovits, Aya · Inventors: Jakobovits, Aya; Raitano, Arthur B.; Challita-Eid, Pia M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel gene 254P1D6B and its encoded protein and variants thereof, are , described wherein 254P1D6B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 254P1D6B provides a diagnostic prognostic, prophylactic and/or , therapeutic target for cancer. The 254P1D6B gene or fragment thereof or its , encoded protein, or variants thereof or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 254P1D6B can be used in active or passive immunization.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 23, 2004 and granted May 13, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 23, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 23, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.